Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anti-Müllerian hormone (AMH), produced by growing pre-antral and early antral ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum AMH concentrations are elevated during reproductive life in anovulatory women, especially in those patients exhibiting polycystic ovaries (PCO). The current study was designed to investigate whether the decrease in AMH serum concentrations over time is different comparing women with normogonadotrophic anovulation [World Health Organization (WHO) group 2 (including polycystic ovary syndrome (PCOS)] and normo-ovulatory controls. METHODS AND RESULTS: AMH serum levels were assessed on two occasions in 98 patients suffering from WHO 2 anovulatory infertility as well as in 41 normo-ovulatory premenopausal women. Median time interval between both visits was 2.6 years (range 0.3-9.0) for WHO 2 patients compared with 1.6 years (range 1.0-7.3) in controls. Serum AMH concentrations were significantly (P < 0.0001) elevated on both occasions in WHO 2 patients (AMH1, median = 7.5 microg/l, range 0.1-35.8; and AMH2, median = 6.7 microg/l, range 0.0-30.6) compared with controls (AMH1, median = 2.1 microg/l, range 0.1-7.4; and AMH2, median = 1.3 microg/l, range 0.0-5.0). Regression analysis, corrected for age, indicated a significant relative decrease in serum AMH concentrations over time for both groups (P < 0.001). However, the decline in serum AMH in WHO 2 patients was significantly less compared with controls (P = 0.03). CONCLUSION: The present longitudinal study shows that serum AMH concentrations decrease over time both in women presenting with WHO 2 anovulatory infertility and in normo-ovulatory controls. The decrease in WHO 2 patients is less pronounced despite distinctly elevated concentrations. This observation may suggest retarded ovarian ageing and hence a sustained reproductive life span in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The variability of female reproductive ageing
te Velde, E. R. (2002) · Human Reproduction Update · doi:10.1093/humupd/8.2.141 · Cited by 1,214
Ultrasound assessment of the polycystic ovary: international consensus definitions
Balen, A. H., Laven, J. S. E., Tan, S.-L., & Dewailly, D. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg044 · Cited by 1,015 · cited 1×
“10.0 ml) of at least one ovary (Balen et al., 2003).”
BackgroundInfluentialSelf-citationPigny, P., Merlen, E., Robert, Y., Cortet-Rudelli, C., Decanter, C., Jonard, S., & Dewailly, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030727 · Cited by 709 · cited 2×
“Recently, AMH levels were found to be elevated in anovulatory and PCOS patients compared with normal controls (Cook et al., 2002; Pigny et al., 2003; Laven et al., 2004).”
BackgroundManipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*
Fauser, B. C. J. M., & van Heusden, A. M. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0290 · Cited by 509
Self-citationNew Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory Infertility
Laven, J. S. E., Imani, B., Eijkemans, M. J. C., & Fauser, B. C. J. M. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200211000-00022 · Cited by 235 · cited 2×
“Chronic anovulation is a common cause of infertility and it is diagnosed in , 20 –25% of couples with fertility problems (ESHRE Capri Workshop Group, 1995; Laven et al., 2002).”
BackgroundSelf-citation
Cited by
Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976
Self-citationLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012) · Menopause · doi:10.1097/gme.0b013e31824d8f40 · Cited by 1,705
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & for the STRAW + 10 Collaborative Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3362 · Cited by 1,325
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)
La Marca, A., Sighinolfi, G., Radi, D., Argento, C., Baraldi, E., Artenisio, A. C., Stabile, G., & Volpe, A. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp036 · Cited by 956
Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & for the Straw +10 Collaborative Group (2012) · Climacteric · doi:10.3109/13697137.2011.650656 · Cited by 817
Anti-Müllerian hormone: a new marker for ovarian function
Visser, J. A., de Jong, F. H., Laven, J. S. E., & Themmen, A. P. N. (2006) · Reproduction · doi:10.1530/rep.1.00529 · Cited by 799
Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications
Broer, S. L., Broekmans, F. J. M., Laven, J. S. E., & Fauser, B. C. J. M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu020 · Cited by 683
Day, F. R., Hinds, D. A., Tung, J. Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjonnes, A., Broer, L., Dunger, D. B., Halldorsson, B. V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9464 · Cited by 459
“Higher AMH concentrations consequently inhibit the recruitment of further primordial follicles, possibly representing more efficient use of the primordial ovarian pool 20 .”
BackgroundA Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause
Kelsey, T. W., Wright, P., Nelson, S. M., Anderson, R. A., & Wallace, W. H. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022024 · Cited by 457
La Marca, A., & Volpe, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02533.x · Cited by 369
Consensus on women's health aspects of polycystic ovary syndrome (PCOS)
The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, Fauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, H., Chang, R. J., Yildiz, B. O., et al. (2012) · Human Reproduction · doi:10.1093/humrep/der396 · Cited by 366
Anti-Mullerian hormone (AMH): what do we still need to know?
La Marca, A., Broekmans, F. J., Volpe, A., Fauser, B. C., Macklon, N. S., & on behalf of the ESHRE Special Interest Group for Reproductive Endocrinology - AMH Round Table (2009) · Human Reproduction · doi:10.1093/humrep/dep210 · Cited by 327
Autophagy in ovary and polycystic ovary syndrome: role, dispute and future perspective
Kumariya, S., Ubba, V., Jha, R. K., & Gayen, J. R. (2021) · Autophagy · doi:10.1080/15548627.2021.1938914 · Cited by 305
Piltonen, T., Morin-Papunen, L., Koivunen, R., Perheentupa, A., Ruokonen, A., & Tapanainen, J. S. (2005) · Human Reproduction · doi:10.1093/humrep/deh850 · Cited by 294
Tehrani, F., Simbar, M., Tohidi, M., Hosseinpanah, F., & Azizi, F. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-39 · Cited by 290
Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles
Ebner, T., Sommergruber, M., Moser, M., Shebl, O., Schreier-Lechner, E., & Tews, G. (2006) · Human Reproduction · doi:10.1093/humrep/del127 · Cited by 281
Iliodromiti, S., Kelsey, T. W., Anderson, R. A., & Nelson, S. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1393 · Cited by 280
Rico, C., Fabre, S., Medigue, C., Clemente, N. D., Clement, F., Bontoux, M., Touze, J.-L., Dupont, M., Briant, E., Remy, B., et al. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.072157 · Cited by 275
Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update
Abraham Gnanadass, S., Divakar Prabhu, Y., & Valsala Gopalakrishnan, A. (2021) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05951-2 · Cited by 272
Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1677 · Cited by 241
“A protective effect could also be obtained by the possibly delayed menopause (37), also indicated by the decreased FSH levels compared with controls (18).”
BackgroundMullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer, D. B., & MacLaughlin, D. T. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.02.014 · Cited by 220
Nardo, L. G., Yates, A. P., Roberts, S. A., Pemberton, P., & Laing, I. (2009) · Human Reproduction · doi:10.1093/humrep/dep225 · Cited by 188
Is foetal hyperexposure to androgens a cause of PCOS?
Filippou, P., & Homburg, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx013 · Cited by 152
The role of AMH in the pathophysiology of polycystic ovarian syndrome
Garg, D., & Tal, R. (2016) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2016.04.007 · Cited by 150
Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause
Welt, C. K., & Carmina, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2375 · Cited by 148
Schmidt, J., Brännström, M., Landin-Wilhelmsen, K., & Dahlgren, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2959 · Cited by 113
Is polycystic ovary syndrome an exception for reproductive aging?
Ramezani Tehrani, F., Solaymani-Dodaran, M., Hedayati, M., & Azizi, F. (2010) · Human Reproduction · doi:10.1093/humrep/deq088 · Cited by 111
Lemos, N. A., Arbo, E., Scalco, R., Weiler, E., Rosa, V., & Cunha-Filho, J. S. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.04.048 · Cited by 110
Endometriosis and polycystic ovary syndrome are diametric disorders
Dinsdale, N. L., & Crespi, B. J. (2021) · Evolutionary Applications · doi:10.1111/eva.13244 · Cited by 90
AMH as part of the diagnostic PCOS workup in large epidemiological studies
Piltonen, T. T., Komsi, E., Morin-Papunen, L. C., Korhonen, E., Franks, S., Järvelin, M.-R., Arffman, R. K., & Ollila, M.-M. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad065 · Cited by 58
Prediction of age at menopause in women with polycystic ovary syndrome
Minooee, S., Ramezani Tehrani, F., Rahmati, M., Mansournia, M. A., & Azizi, F. (2018) · Climacteric · doi:10.1080/13697137.2017.1392501 · Cited by 55
Evolutionary determinants of polycystic ovary syndrome: part 2
Fessler, D. M. T., Natterson-Horowitz, B., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.016 · Cited by 44
Metadata
- Authors
- Mulders, A. G. M. G. J.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-24
- Volume
- 19
- Issue
- 9
- Pages
- 2036-2042
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2149345691
- Cited by
- 155
- References
- 7
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.